FiercePharmaOriginal article
{"a":[{"_":"PMCPA sanctions melatonin drugmaker over misleading information","$":{"href":"/marketing/pmcpa-sanctions-melatonin-drugmaker-over-misleading-information","hreflang":"en"}}]}
RegulatoryAdaflexNegative
AI Analysis
Summary
The U.K. pharma marketing watchdog (PMCPA) sanctioned AGB Pharma for misleadingly implying a lack of fertility considerations for its melatonin medicine, Adaflex, in violation of marketing regulations.
Outcome Details
PMCPA sanction for misleading marketing implying lack of fertility considerations
Importance:3/10
Sentiment:
-0.75
regulatorymarketingcompliancemelatoninPMCPAUK
Related Companies
Read the original article
Published by FiercePharma on July 29, 2026 7:20 AM